Detalhe da pesquisa
1.
DRUG EVALUATION AND DECISION MAKING IN CATALONIA: DEVELOPMENT AND VALIDATION OF A METHODOLOGICAL FRAMEWORK BASED ON MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR ORPHAN DRUGS.
Int J Technol Assess Health Care
; 33(1): 111-120, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28434413
2.
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab.
Appl Health Econ Health Policy
; 18(1): 5-16, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31696433
3.
Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties.
Orphanet J Rare Dis
; 13(1): 206, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30442155
4.
Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.
BMJ Open
; 7(9): e017358, 2017 Sep 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28893754
5.
Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).
Orphanet J Rare Dis
; 12(1): 50, 2017 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28283046
6.
Does orphan drug legislation really answer the needs of patients?
Lancet
; 371(9629): 2041-4, 2008 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-18555916